Sonnet BioTherapeutics Faces Nasdaq Non-Compliance Notice

Sonnet BioTherapeutics Holdings ( (SONN) ) just unveiled an announcement.

On May 30, 2025, Sonnet BioTherapeutics Holdings received a notice from Nasdaq indicating non-compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. The company reported stockholders’ equity of $662,262, significantly below the $2.5 million requirement. Sonnet has until July 14, 2025, to submit a compliance plan, with potential extensions up to 180 days. Failure to regain compliance could lead to delisting, impacting liquidity, trading volume, and the company’s ability to raise capital, thereby affecting its business operations and investor confidence.

The most recent analyst rating on (SONN) stock is a Buy with a $240.00 price target. To see the full list of analyst forecasts on Sonnet BioTherapeutics Holdings stock, see the SONN Stock Forecast page.

Spark’s Take on SONN Stock

According to Spark, TipRanks’ AI Analyst, SONN is a Neutral.

Sonnet BioTherapeutics Holdings receives a score of 48, primarily due to its challenging financial position characterized by significant losses and reliance on external financing. Despite these financial hurdles, recent corporate developments, including new patents and promising drug data, provide a positive outlook for future growth. However, the stock remains speculative due to its financial instability and negative valuation metrics.

To see Spark’s full report on SONN stock, click here.

More about Sonnet BioTherapeutics Holdings

Sonnet BioTherapeutics Holdings, Inc. operates in the biotherapeutics industry, focusing on the development of innovative biologic drugs designed to treat cancer and other serious diseases.

Average Trading Volume: 41,069

Technical Sentiment Signal: Sell

Current Market Cap: $3.7M

See more data about SONN stock on TipRanks’ Stock Analysis page.